What's Happening?
Corcept Therapeutics has presented new data from its Phase 3 ROSELLA trial at the ESMO 2025 Annual Meeting, demonstrating that relacorilant plus nab-paclitaxel improves progression-free survival (PFS) and overall survival (OS) in patients with platinum-resistant
ovarian cancer. The trial showed a 30% reduction in disease progression risk and a 31% reduction in death risk for patients receiving relacorilant compared to nab-paclitaxel monotherapy. The study highlights relacorilant's ability to overcome chemotherapy resistance, particularly in patients who have previously been treated with PARP inhibitors.
Why It's Important?
The ROSELLA trial results are significant as they offer a new therapeutic option for patients with platinum-resistant ovarian cancer, a group with limited treatment options and poor prognosis. Relacorilant's ability to improve survival outcomes without increasing safety burdens could change the treatment landscape for ovarian cancer, providing hope for patients who have exhausted other therapies. The findings may also encourage further research into relacorilant's potential in other gynecological cancers.
What's Next?
Corcept plans to expand its Phase 2 BELLA trial to evaluate relacorilant in additional cancer settings, including platinum-sensitive ovarian cancer and endometrial cancer. The FDA has accepted Corcept's New Drug Application for relacorilant in platinum-resistant ovarian cancer, with a decision expected by July 2026. These developments could lead to broader clinical use and regulatory approval, potentially improving patient outcomes in various cancer types.
Beyond the Headlines
The success of relacorilant may prompt discussions on the role of cortisol modulation in cancer treatment, potentially leading to new therapeutic strategies. Ethical considerations regarding access to innovative treatments and their cost may arise, impacting healthcare policy and patient care.
